Your browser doesn't support javascript.
loading
A nanobody interaction with SARS-COV-2 Spike allows the versatile targeting of lentivirus vectors.
Alfadhli, Ayna; Bates, Timothy A; Barklis, Robin Lid; Romanaggi, CeAnn; Tafesse, Fikadu G; Barklis, Eric.
Afiliación
  • Alfadhli A; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Bates TA; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Barklis RL; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Romanaggi C; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Tafesse FG; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Barklis E; Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, Oregon, USA.
J Virol ; 98(9): e0079524, 2024 Sep 17.
Article en En | MEDLINE | ID: mdl-39207135
ABSTRACT
While investigating methods to target gene delivery vectors to specific cell types, we examined the potential of using a nanobody against the SARS-CoV-2 Spike protein receptor-binding domain to direct lentivirus infection of Spike-expressing cells. Using four different approaches, we found that lentiviruses with surface-exposed nanobody domains selectively infect Spike-expressing cells. Targeting is dependent on the fusion function of the Spike protein, and conforms to a model in which nanobody binding to the Spike protein triggers the Spike fusion machinery. The nanobody-Spike interaction also is capable of directing cell-cell fusion and the selective infection of nanobody-expressing cells by Spike-pseudotyped lentivirus vectors. Significantly, cells infected with SARS-CoV-2 are efficiently and selectively infected by lentivirus vectors pseudotyped with a chimeric nanobody protein. Our results suggest that cells infected by any virus that forms syncytia may be targeted for gene delivery by using an appropriate nanobody or virus receptor mimic. Vectors modified in this fashion may prove useful in the delivery of immunomodulators to infected foci to mitigate the effects of viral infections.IMPORTANCEWe have discovered that lentiviruses decorated on their surfaces with a nanobody against the SARS-CoV-2 Spike protein selectively infect Spike-expressing cells. Infection is dependent on the specificity of the nanobody and the fusion function of the Spike protein and conforms to a reverse fusion model, in which nanobody binding to Spike triggers the Spike fusion machinery. The nanobody-Spike interaction also can drive cell-cell fusion and infection of nanobody-expressing cells with viruses carrying the Spike protein. Importantly, cells infected with SARS-CoV-2 are selectively infected with nanobody-decorated lentiviruses. These results suggest that cells infected by any virus that expresses an active receptor-binding fusion protein may be targeted by vectors for delivery of cargoes to mitigate infections.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lentivirus / Anticuerpos de Dominio Único / Glicoproteína de la Espiga del Coronavirus / Vectores Genéticos / SARS-CoV-2 Límite: Humans Idioma: En Revista: J Virol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lentivirus / Anticuerpos de Dominio Único / Glicoproteína de la Espiga del Coronavirus / Vectores Genéticos / SARS-CoV-2 Límite: Humans Idioma: En Revista: J Virol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...